sinogliatin

Sinogliatin is a **novel 4th-generation glucokinase activator (GKA)** developed primarily for the treatment of **type 2 diabetes mellitus**. It acts by selectively activating glucokinase—the glucose-sensing enzyme in pancreatic beta cells and hepatocytes—thereby increasing glucose-dependent insulin secretion and improving glycemic control. Unlike earlier GKAs, sinogliatin’s chemistry more closely mimics the natural enzyme kinetics and eliminates the formation of major human metabolites, resulting in a safer profile with low hypoglycemia risk. Clinical studies have shown dose-dependent reductions in fasting, postprandial, and 24-hour glucose levels, robust increases in post-meal C-peptide and insulin, and excellent oral safety and tolerability. Sinogliatin is the **S,S-isomer** (specific stereochemistry) of the related compound dorzagliatin, which is the S,R-isomer[1][3][5][7][9].

Other names

sinogliatinHMS5552HMS-5552HMS 5552RO-5305552RO5305552RO 5305552S-isomer of dorzagliatin